Orexo: Zubsolv stabilised during the quarter - Nordea

While Zubsolv sales and EBIT for Q3 were better than expected, Orexo's future key portfolio, DTx, is still not delivering according to our short-term expectations. As a result of lowering our estimates for DTx sales for the next five years, we lower our valuation range to SEK 44-58 (55-71). Marketing material commissioned by Orexo.

Länk till analysen i sin helhet: https://research.nordea.com/api/reportfileapi?id=724844&channel=finwire